verapamil has been researched along with Impaired Glucose Tolerance in 2 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We sought to test the hypothesis that a fixed-dose combination of trandolapril/verapamil-SR (T/V) is superior to a fixed-dose combination of losartan/hydrochlorothiazide (L/H) on glucose tolerance in hypertensive patients with impaired glucose tolerance (IGT)." | 5.12 | Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. ( Bacher, P; Bakris, G; Fakouhi, K; Hewkin, A; Kipnes, M; Molitch, M; Sarafidis, P; Sowers, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakris, G | 1 |
| Molitch, M | 1 |
| Hewkin, A | 1 |
| Kipnes, M | 1 |
| Sarafidis, P | 1 |
| Fakouhi, K | 1 |
| Bacher, P | 1 |
| Sowers, J | 1 |
| O'Malley, KJ | 1 |
| Bouldin, MJ | 1 |
| Riche, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Hyzaar® on Glucose Tolerance in Subjects With Metabolic Syndrome[NCT00234858] | Phase 4 | 280 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Comparison of Single and Combination Diuretics in Low-Renin Hypertension[NCT02351973] | Phase 4 | 423 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | ||
| A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes[NCT02887677] | Phase 4 | 85 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to On February 2019 Astra-Zeneca Greece decided to stop the financial support of the study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for verapamil and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
Topics: Adult; Antihypertensive Agents; Blood Glucose; Body Mass Index; Body Size; Body Weight; Drug Therapy | 2006 |
1 other study available for verapamil and Impaired Glucose Tolerance
| Article | Year |
|---|---|
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome: response to Bakris et al.
Topics: Antihypertensive Agents; Blood Glucose; Drug Therapy, Combination; Female; Glucose Intolerance; Gluc | 2007 |